ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bilastine

Also written as “Bilastine”, “Bilastine oral dispersible tablets” and “Bilaxten oral dispersible tablets”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Conjunctivitis, Allergic · Urticaria · Rhinitis, Allergic · Asthma, led by 4 companies.

Drug pageBilastine: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 9, 200719 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Faes Farmaits history only140 open or runningphase 3since Jan 9, 2007Jan 8, 2007none ahead
Menarini Group30 open or runningphase 4since Oct 13, 2015Oct 13, 2015none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jun 20, 2025Jun 20, 2025none ahead
Yuhanits history only10 open or runningphase 3since Jul 20, 2011Jul 20, 2011none ahead

Also a collaborator on its studies: ORA, Dynamic Science S.L., Allied Research International and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Menarini Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2015First study: phase 4 study in Rhinitis, AllergicFirst studyNCT02576041 · 19 enrolled · Italy
  2. Apr 28, 2016Phase 4 study in AsthmaNCT02761252 · 454 enrolled · Croatia, Czechia, Germany and more
  3. Aug 3, 2018Phase 1 study in PharmacokineticsNCT03633760 · 24 enrolled · China

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor inverse agonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
desloratadineruleOrganonphase 440
fexofenadineruleSanofiphase 438
DiphenhydramineruleJohnson & Johnsonphase 416

Studies

All 3 Menarini Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03633760Pharmacokinetics · China1UNKNOWNApr 30, 201924
NCT02761252Asthma · Croatia, Czechia, Germany and more4CompletedNov 24, 2016454
NCT02576041Rhinitis, Allergic · Italy4CompletedDec 201519

How it is read

Names in the registry

  • “Bilastine”, 13 entries
  • “bilastine”, 2 entries
  • “Bilastine oral dispersible tablets”, 1 entry
  • “Bilaxten oral dispersible tablets”, 1 entry
  • “Bilastine 0.2%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.